Monographie - Scopolamine N-butyl bromide

Viimeisin päivitys :
19/11/2024

Scopolamine N-butyl bromide

Kemiallinen rakenne

Kauppanimi

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Buscapina	Espanja
Buscolysin	Puola
Buscopan	Australia, Belgia, Brasilia, Egypti, Hollanti, Islanti, Itävalta, Kanada, Luxemburg, New Zealand, Norja, Portugali, Ruotsi, Saksa, Suomi, Sveitsi, Tunisia, Turkki, Yhdistyneet arabiemiirikunnat
Butilbromuro de hioscina	Argentiina, Kolumbia
Cifespasmo	Argentiina
Colobolina	Argentiina
Dolopina	Ecuador
Escopolamina N butyl bromuro	Chile
Hiocin	Venezuela
Hioscina	Argentiina, Kolumbia, Marokko
Hioscina butil bromuro	Kolumbia, Marokko
Hyocidic	Iran
Hyoscine	Australia
Hyoscine hydrobromide	Kanada
Hyotex	Iran
Pasmodina Drawer	Argentiina
Rupe N	Argentiina
Scoburen	Ranska
Selpirans	Venezuela
Spasmopan	Tunisia
Xemol	Turkki

Viitteet : Scopolamine N-butyl bromide

	tyyppi	julkaisu
1230	Lehti	Regnard C, Pashley S, Westrope F. Anti-emetic / diamorphine mixture compatibility in infusion pumps. Br J Pharm Pract 1986 ; 8: 218-220.
1232	Lehti	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1405	Lehti	Peterson GM, Miller KA, Galloway JG, Dunne PF. Compatibility and stability of fentanyl admixtures in polypropylene syringes. J Clin Pharm Ther 1998 ; 23: 67-72.
1757	Lehti	Schrijvers D, Tai-Apin C, De Smet MC, Cornil P, Vermorken JB, Bruyneel P. Determination of compatibility and stability of drugs used in palliative care. J Clin Pharm Ther 1998 ; 23: 311-314.
1847	Lehti	Anacardo R, Perilli O, Bartolini S, Gentile MM, Mazzeo P, Carlucci G. Physicochemical compatibility between ketoprofen kysine salt injections (Artrosilene®) and pharmaceutical products frequently used for combined therapy by intravenous administration. J Pharm Biomed Anal 2003 ; 32, 6: 1235-1241.
1966	Lehti	Barcia E, Reyes R, Azuara L, Sànchez Y, Negro S. Stability and compatibility of binary mixtures of morphine hydrochloride with hyoscine-n-butyl bromide. Support Care Cancer 2005 ; 13, 4: 239-245.
1970	Lehti	Barcia E, Reyes R, Azuara M.L, S?nchez Y, Negro S. Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer patients in palliative care. Support Care Cancer 2003 ; 11, 2: 107-113.
1971	Lehti	Azuara ML, Sanchez Y, Reyes R, Barcia E. Physical compatibility and in vivo evaluation of drug mixtures forsubcutaneous infusion to cancer patients in palliative care. Support Care Cancer 2001
2055	Lehti	Negro S, Reyes R, Azuara ML, Sanchez Y, Barcia E. Morphine, haloperidol and hyoscine N-butyl bromide combined in sc infusion solutions : compatibility and stability evaluation in terminal oncology patients. Int J Pharm 2006 ; 307: 278-284.
2125	Lehti	Gardiner PR. Compatibility of an injectable oxycodone formulation with typical diluents, syringes, tubings, infusion bags and drugs for potential co-administration. Hospital Pharmacist 2003 ; 10: 354-361.
2176	Lehti	Barcia E, Martin A, Azuara ML, Sanchez Y, Negro S. Tramadol and hyoscine N-butyl bromide combined in infusion solutions: compatibility and stability. Support Care Cancer 2007 ; 15: 57-62.
2900	Lehti	Hines S, Pleasance S. Compatibility of an injectable high strength oxycodone formulation with typical diluents, syringes, tubings,infusion bags and drugs for potential co-administration. EJHP 2009 ; 15, 5: 32-38.
3132	Lehti	Negro S, Martin A, Azuara L, Sanchez Y, Barcia E. Compatibility and stability of ternary admixtures of tramadol, haloperidol, and hyoscine. J Palliat Med 2010 ; 13, 3: 273-277.
4404	ilmoitus	Müller U, Haller F, Wiedemeier P, Steuer C. Compatibility studies of seven commonly used drugs for parenteral administration in palliative care. JFSPH 2019 2019

Mentions Légales